HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma.

Abstract
Intravenous-bolus etoposide has modest activity in sarcomas when given daily for 3-5 days. Low frequent doses theoretically inhibit topoisomerase II activity over a longer duration and have been reported to have increased activity in small-cell lung cancer. A phase I trial of oral etoposide resulted in partial responses in two patients with soft-tissue sarcomas. To estimate more accurately the response rate for daily oral etoposide in sarcomas, we treated 25 patients with 50 mg/m2 per day by mouth for 21 days every 4 weeks. Treatment-related toxicity included > or = grade 2 neutropenia in 6 of the 25 patients and thrombocytopenia in 3. One brief partial response was observed (4%; 95% confidence interval for true response rate, 0-11%). Disease stabilized in five patients for periods ranging from 3 to 18 months. At this dose and on this schedule, daily oral etoposide appears to have little activity against soft-tissue sarcomas.
AuthorsJ D Licht, R Mazanet, P J Loehrer, R Gonin, K H Antman
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 34 Issue 1 Pg. 79-80 ( 1994) ISSN: 0344-5704 [Print] Germany
PMID8174207 (Publication Type: Clinical Trial, Clinical Trial, Phase IV, Journal Article)
Chemical References
  • Etoposide
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Drug Administration Schedule
  • Etoposide (administration & dosage, therapeutic use)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Sarcoma (drug therapy, secondary)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: